VION Biosciences Acquires BioAssay Systems
February 5, 2025
VION Biosciences acquired Hayward, California–based BioAssay Systems in January 2025 as the fourth add-on for its life‑science products platform. The deal adds BioAssay Systems’ enzymatic and high‑throughput assay kits, reagents and analytical services to VION’s proprietary product portfolio to accelerate capability expansion for drug discovery and life‑science research customers.
- Buyers
- VION Biosciences
- Targets
- BioAssay Systems
- Platforms
- VION Biosciences
- Industry
- Biotechnology
- Location
- California, United States
- Transaction Type
- Addon
Explore More
Related Acquisitions
-
VION Biosciences Acquires Prolytix
September 8, 2026
Biotechnology
VION Biosciences announced the closing of its acquisition of Prolytix, a provider of regulated bioanalytical and CMC services, research reagents, and custom sample collection products. The deal is intended to strengthen VION’s integrated platform across biopharma services and diagnostic workflow inputs, including regulated large-molecule testing and workflow-critical reagents and IVD materials.
-
VION Biosciences Acquires Cellular Technology Limited (CTL)
April 8, 2026
Healthcare Services
VION Biosciences has completed its acquisition of Cellular Technology Limited (CTL), a provider of functional immune monitoring analyzers, software, consumables, and services. The deal strengthens VION’s workflow-oriented immune medicine capabilities by adding CTL’s ELISPOT/FluoroSpot platforms, regulatory-grade software, and an established global installed base.
-
VION Biosciences Acquires Ansh Labs
August 29, 2024
Biotechnology
VION Biosciences, the life-science platform backed by Iron Path Capital, has acquired Ansh Labs, an immunoassay development and reagent manufacturer based in Houston, Texas. The add-on expands VION's diagnostics capabilities — adding GMP IVD manufacturing and ISO 13485 certification — and broadens the platform's product and service offerings for clinical diagnostics, research, and pharmaceutical development.
-
VION Biosciences Acquires Echelon Biosciences
August 22, 2024
Biotechnology
VION Biosciences, the life-science platform backed by Iron Path Capital, has acquired Salt Lake City-based Echelon Biosciences, a specialist supplier of lipid-based excipients and lipid nanoparticles. The add-on strengthens VION's capabilities in lipid synthesis and lipid nanoparticle technology to support mRNA and gene-therapy development and advances the platform toward drug manufacturing while keeping Echelon’s leadership and operations intact.
-
Biosynth Carbosynth Acquires Aalto Bio Reagents
May 26, 2022
Biotechnology
Biosynth Carbosynth, a Swiss life‑sciences supplier, has acquired Aalto Bio Reagents, a Dublin‑based developer and provider of biological materials for in‑vitro diagnostics (IVD) and vaccine development. The deal strengthens Biosynth’s IVD and vaccine product portfolio and expands its capabilities to serve diagnostics and vaccine development customers worldwide.
-
PerkinElmer Acquires Cisbio Bioassays from Abénex
April 26, 2019
Biotechnology
PerkinElmer has acquired Cisbio Bioassays from Abénex (with Cisbio management supporting the sale). Cisbio, headquartered in Codolet, France, is a manufacturer of HTRF assay kits, reagents and custom assay services with more than 200 employees; the acquisition expands PerkinElmer's life‑sciences reagent and screening technology portfolio.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.